
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AID CRISPR Activation Plasmid (h) | sc-401542-ACT | 20 µg | $397.00 |
Human AICDA encodes activation-induced cytidine deaminase (AID), a DNA/RNA-editing enzyme that catalyzes cytidine-to-uridine deamination on single-stranded DNA during transcription. AID is essential for antibody diversification through somatic hypermutation and class switch recombination in germinal center B cells, linking its activity to DNA repair processes including base excision repair and mismatch repair. Tight regulation of AID is required to limit off-target mutagenesis, as dysregulated or ectopic expression can increase genomic instability and contribute to chromosomal translocations and mutation accumulation. Accordingly, AICDA is widely studied in pathways governing adaptive immunity, B cell differentiation, and mechanisms of mutation-driven oncogenic transformation.
AID CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous AICDA expression without altering the underlying DNA sequence.
AID CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the AICDA locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the AICDA transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous AID expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native AICDA locus and enabling the study of AID-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of AID pathway restoration in tumor cells with silenced or reduced AICDA expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.